Anika Therapeutics received CE Mark approval for ORTHOVISC®-T injection indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
ORTHOVISC-T is designed to lubricate damaged tendons to promote gliding and support repair. The biocompatible, non-animal-derived and non-inflammatory hyaluronic acid formula is similar ORTHOVISC and MONOVISC® viscosupplements.
Also within 2016, the company received CE Mark Approval and commenced EU launch of CINGAL®, its third-generation viscosupplement, to treat osteoarthritis-related pain.
Anika Therapeutics received CE Mark approval for ORTHOVISC®-T injection indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
ORTHOVISC-T is designed to lubricate damaged tendons to promote gliding and support repair. The biocompatible, non-animal-derived and non-inflammatory hyaluronic acid...
Anika Therapeutics received CE Mark approval for ORTHOVISC®-T injection indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
ORTHOVISC-T is designed to lubricate damaged tendons to promote gliding and support repair. The biocompatible, non-animal-derived and non-inflammatory hyaluronic acid formula is similar ORTHOVISC and MONOVISC® viscosupplements.
Also within 2016, the company received CE Mark Approval and commenced EU launch of CINGAL®, its third-generation viscosupplement, to treat osteoarthritis-related pain.
Copy to clipboard 
